Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 13.49% and Operating profit at -10.80% over the last 5 years
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 8,502 Million (Large Cap)
NA (Loss Making)
NA
0.00%
-0.11
-13.84%
6.81
Revenue and Profits:
Net Sales:
62 Million
(Quarterly Results - Sep 2025)
Net Profit:
-60 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
56.37%
0%
56.37%
6 Months
20.7%
0%
20.7%
1 Year
69.37%
0%
69.37%
2 Years
141.76%
0%
141.76%
3 Years
72.93%
0%
72.93%
4 Years
27.57%
0%
27.57%
5 Years
-33.96%
0%
-33.96%
Tinavi Medical Technologies Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.49%
EBIT Growth (5y)
-10.80%
EBIT to Interest (avg)
-47.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.14
Tax Ratio
22.35%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.21
EV to EBIT
-52.06
EV to EBITDA
-75.74
EV to Capital Employed
6.60
EV to Sales
31.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-12.67%
ROE (Latest)
-11.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
62.20
33.80
84.02%
Operating Profit (PBDIT) excl Other Income
-55.60
-26.40
-110.61%
Interest
1.60
2.30
-30.43%
Exceptional Items
2.60
0.00
Consolidate Net Profit
-60.50
-29.70
-103.70%
Operating Profit Margin (Excl OI)
-894.50%
-1,118.00%
22.35%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 84.02% vs -34.75% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -103.70% vs 15.62% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
178.90
209.20
-14.48%
Operating Profit (PBDIT) excl Other Income
-115.00
-167.10
31.18%
Interest
9.20
6.50
41.54%
Exceptional Items
-0.20
0.10
-300.00%
Consolidate Net Profit
-121.10
-161.30
24.92%
Operating Profit Margin (Excl OI)
-883.30%
-1,012.20%
12.89%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -14.48% vs 34.27% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 24.92% vs -43.63% in Dec 2023
About Tinavi Medical Technologies Co., Ltd. 
Tinavi Medical Technologies Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






